Recognizing the Role of Capmatinib for METex14 in NSCLC

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLCПодробнее

The importance of METex14 testing in NSCLCПодробнее

Investigating MET Exon 14 Mutations in Patients With NSCLCПодробнее

Dr Navdeep Singh | CAPMATINIB Unlocking The unMET need in METex14 skipping NSCLCПодробнее

The challenges of treating METex14 NSCLCПодробнее

Dr. Le on the Rationale for Tepotinib in METex14-Mutant NSCLCПодробнее

Assessing capmatinib for lung cancerПодробнее

FDA Priority Review of Capmatinib for METex14-Mutated NSCLCПодробнее

GEOMETRY Study Confirms Importance of Testing for METex14 Alteration in Advanced NSCLCПодробнее

FDA Approves Capmatinib for Advanced Lung CancerПодробнее

Dr Ashish Singh - Capmatinib The Unmet Need In MET Ex14 Skipping Mutated NSCLCПодробнее

MET Exon 14 Mutations in mNSCLCПодробнее

What is Capmatinib? Efficacy and Safety of a Targeted Cancer Drug Used in a MET Gene AlterationПодробнее

Dr. Reckamp on Pivotal Data in METex14-Altered NSCLCПодробнее

Off-Label Crizotinib for the Treatment of METex14-Mutated NSCLCПодробнее

Personalized therapy for NSCLC: Biomarker testing, treatment & management in MET alterationsПодробнее

METalmark: amivantamab and capmatinib in advanced NSCLCПодробнее

Capmatinib vs Docetaxel in METex14 NSCLC | GreoMETry-III | Dr. Bharat Bhosale | CRSF 2023Подробнее

VISION: tepotinib in MET exon 14 skipping NSCLCПодробнее